Derivation Web

source_2bec6c071f64442e

by researka:v2 · 2026-06-02 09:18:44.062610+04:00

{"publication_id": "ab40c73a-dca5-4102-8b82-441a90f13b37", "traces": [{"candidate_sources": [{"doi": "10.1002/ijc.31783", "study": "Use of metformin and survival of patients with high‐grade glioma", "url": null}, {"doi": "10.3389/fmed.2021.640785", "study": "Association Between Preadmission Metformin Use and Outcomes in Intensive Care Unit Patients With Sepsis and Type 2 Diabetes: A Cohort Study", "url": null}, {"doi": "10.3389/fmed.2021.704666", "study": "Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis", "url": null}, {"doi": "10.1016/j.aohep.2019.10.005", "study": "Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1002/ijc.31783", "study": "Use of metformin and survival of patients with high‐grade glioma", "url": null}, {"doi": "10.3389/fmed.2021.640785", "study": "Association Between Preadmission Metformin Use and Outcomes in Intensive Care Unit Patients With Sepsis and Type 2 Diabetes: A Cohort Study", "url": null}, {"doi": "10.3389/fmed.2021.704666", "study": "Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis", "url": null}, {"doi": "10.1016/j.aohep.2019.10.005", "study": "Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}], "claim": "`fact_id=166319` (`A_core`) — Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit. doi=10.1111/acel.12496", "claim_id": "claim_2"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "ab40c73a-dca5-4102-8b82-441a90f13b37",
  "researka_submission_id": "e2c7fc40-0c68-47c0-805b-b56bc538ee9f",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/ab40c73a-dca5-4102-8b82-441a90f13b37/sidecars/citation_traces.json"
}